These results were corroborated in NSGS mice transplanted with FLT3-ITD+ AML blasts and then treated with miRisten+ AC220 or SCR+ AC220 for 3 weeks (Additional file 1: Fig. S15a). Here, FLT3 is linked to acute myeloid leukemia.